台北民生醫檢所。高檢師。IG日常生活。美食分享。旅遊外拍分享。享瘦人生。
文章搜尋
關鍵字
首頁 » 攝護腺炎/婦科/尿道炎久治不癒檢查專區間質性膀胱炎/
2019/08/09

披衣菌感染對於女性的影響

披衣菌感染對於女性與懷孕婦女的影響 1.輸卵管阻塞或水腫 2.不孕或子宮外孕 3.慢性骨盆腔炎 4.陰道出血 5.子宮頸炎 6.早期破水 7.胎兒體重過輕  8.早產機率大幅提升 9.導致新生兒結膜炎或失明 10.新生兒呼吸道疾病


 
繼續閱讀
2019/02/24

只要用對方法,不管是性病泌尿道感染久治不癒或是皮膚過敏問題,都能迎刃而解

小姐我給你十萬,
你給我摸一下胸好嗎?

美女立馬脫下了衣服,
十分鐘後,
美女: 「你怎麼還不摸?」。

「我沒錢」。



 
繼續閱讀
2019/02/21

年輕男性 V.S 老男人 攝護腺腫大

攝護腺肥大是男性最常見的良性攝護腺增生,其發生與年齡有很大的關係,
在50歲前約20-30百分比,50-60歲有一半的男性有攝護腺肥大,超過80歲以上有90百分比。
而超音波有分兩種檢查方式,ㄧ個經由腹部超音波(TAUS),另一個經直腸超音波(TRUS),來追蹤攝護腺的大小時,每ㄧ位受檢者同一天依序兩種檢查方式,依據所測量的攝護腺大做分析,並所採集的ㄧ年間共有91位男性。
 

民生醫事檢驗所 身體健檢
http://www.minsheng.url.tw/
預約電話02-2769-8340
地址:台北市松山區民生東路5段218號
 
 
繼續閱讀
2018/07/05

台北【婦科】【尿道炎】檢查!上班族久坐大屁股憋尿還會尿道炎

台北【婦科】【尿道炎】檢查!上班族久坐大屁股憋尿還會尿道炎

上班族行政人員,通常都馬一整天坐在辦公椅上處理公務,有時忙到根本沒辦法去上廁所,像是銀行人員、郵政人員,公家機關櫃台等等等,憋尿導致尿道炎是很常有的事,然後好不容易治好了,又有可能尿道炎復發!因為環境如此沒有改善當然有高度復發尿道炎的機會啊!

預防尿道炎注意事項: 
1.注重個人衞生。
2.如廁後應從外陰由前往後至肛門抹拭。
3.房事要注意衞生。
4.避免使用含香料成分的肥皂、陰道灌洗液等。
5.避免穿著太緊身,不透氣的褲子 (包括內褲)。
6.不要憋尿。



民生醫事檢驗所 尿道炎久治不癒檢查
http://www.minsheng.url.tw/
預約電話02-2769-8340
地址:台北市松山區民生東路5段218號

繼續閱讀
2018/03/12

有人吃過泥鰍嗎?

泥鰍

泥鰍含優質蛋白質、脂肪、維生素A、維生素B1、煙酸、鐵、磷、鈣等。其味甘,性平,有補中益氣、養腎生精功效。對調節性功能有較好的作用。泥鰍中含一種特殊蛋白質,有促進精子形成作用。成年男子常食泥鰍可滋補強身。

牡蠣

蠣又稱蚵仔。含有豐富的鋅元素及鐵、磷、鈣、優質蛋白質、糖類等多種維生素。其味咸,性微寒,有滋陰潛陽、補腎澀精功效。男子常食牡蠣可提高性功能及精子的質量。對男子遺精、虛勞乏損、腎虛陽痿等有較好的效果。

淡菜

淡菜又名珠菜、殼菜。含豐富蛋白質、碘、B族維生素、鋅、鐵、鈣、磷等。其味咸,性溫,有溫腎固精、益氣補虛功效。適用于男子性功能障礙、遺精、陽痿、房勞、消渴等癥。男子常食可強壯身體增強性功能。

高檢師提醒您:定期血糖、血脂、高血壓  檢查是很重要的
繼續閱讀
2016/05/17

找到一位披衣菌感染的病友提問的問題!

1.醫師你好,我是在台北民生醫事檢驗所給一位高醫檢師檢查的。
他幫我驗了全套性病,後來有發現披衣菌DNA陽性CHLA IGA 1.38(+)和精液中有發現葡萄球菌感染

2.他請我去看泌尿科拿藥治療,治療了2週 DOXYCYCLINE 

3.第三週第四周改吃TETRACYCLINE
 
4.第五周第六周 LEVOFLOXACIN    

5.第七第八周 ERYTHROMYCIN  

6.第九第十周 CIPROFLOXACIN 特效藥等等 

7.第十周過後甚至連很貴一顆100元的日舒錠也吃了,

8.開藥的醫生說我可能是慢性攝護腺炎

9.可以說網路上疾管局建議的所有披衣菌的藥我都吃過了,經過了半年以上到目前還是沒改善,從披衣菌DNA檢測陽性轉陰性,披衣菌CHLA IGA指數一直是陽性1.14 1.28 最高到1.99 最低有到0.78(-)

10.治療後隔沒多久指數又變高了,我現在尿道開口還是有點怪怪的,小便有時會有透明的球腺液<感覺像是攝護腺液,中醫說是遺精> 

11.我正常的生活作息 正常飲食 咖啡一天一杯 也有大量喝水 沒有不安全性行為 只有自慰的習慣 約3天一次 請醫生幫幫我 
繼續閱讀
2016/04/08

美國CDC;疾病控制與預防中心對於PID說明

Pelvic Inflammatory Disease (PID)

高檢師認為有幾個重點

1.用藥的依據→透過檢查確認是何種感染源所造成的症狀
2.檢查是昂貴的但有其必要性,畢竟台灣與美國醫療制度不同
3.常見的問題包括子宮內膜炎、輸卵管炎 、卵巢膿腫、盆腔腹膜炎,老話一句:
微生物感染部位可能在口腔/陰道/尿道/肛門,尤其在人的免疫系統低下時容易伺機姓被感染

4.避免抗生素濫用造成抗藥性,採降階治療給藥,而最好是能搭配營養補充及運動增加抵抗力
5.尿漿菌、黴漿菌、等漿菌類檢測依然是檢測的重點,我們可以發現美國CDC最後更新日期是2015年6月4號
6.醫療環節中最重要的是透過檢查找到問題,而不是未發現問題而盲目的給藥治療,更不是經驗法則能解決的

 

Pelvic inflammatory disease (PID) comprises a spectrum of inflammatory disorders of the upper female genital tract, including any combination of endometritis, salpingitis, tubo-ovarian abscess, and pelvic peritonitis (728). Sexually transmitted organisms, especially N. gonorrhoeae and C. trachomatis, are implicated in many cases. Recent studies suggest that the proportion of PID cases attributable to N. gonorrhoeae or C. trachomatis is declining; of women who received a diagnosis of acute PID, <50% test positive for either of these organisms (270,729,730). Microorganisms that comprise the vaginal flora (e.g., anaerobes, G. vaginalisHaemophilus influenzae, enteric Gram-negative rods, and Streptococcus agalactiae) have been associated with PID (731). In addition, cytomegalovirus (CMV), M. hominisU. urealyticum, and M. genitalium might be associated with some PID cases (264,265,267,732). Newer data suggest that M. genitalium might play a role in the pathogenesis of PID (270,487) and might be associated with milder symptoms (267), although one study failed to demonstrate a significant increase in PID following detection of M. genitalium in the lower genital tract (733). All women who receive a diagnosis of acute PID should be tested for HIV, as well as gonorrhea and chlamydia, using NAAT. The value of testing women with PID for M. genitalium is unknown, and there is no commercially available diagnostic test that has been cleared by FDA for use in the United States (see Mycoplasma genitalium).

Screening and treating sexually active women for chlamydia reduces their risk for PID (456,682). Although BV is associated with PID, whether the incidence of PID can be reduced by identifying and treating women with BV is unclear (731,734).

Diagnostic Considerations

Acute PID is difficult to diagnose because of the wide variation in symptoms and signs associated with this condition. Many women with PID have subtle or nonspecific symptoms or are asymptomatic. Delay in diagnosis and treatment probably contributes to inflammatory sequelae in the upper reproductive tract. Laparoscopy can be used to obtain a more accurate diagnosis of salpingitis and a more complete bacteriologic diagnosis. However, this diagnostic tool frequently is not readily available, and its use is not easily justifiable when symptoms are mild or vague. Moreover, laparoscopy will not detect endometritis and might not detect subtle inflammation of the fallopian tubes. Consequently, a diagnosis of PID usually is based on imprecise clinical findings (735,736).

Data indicate that a clinical diagnosis of symptomatic PID has a PPV for salpingitis of 65%–90% compared with laparoscopy (737-739). The PPV of a clinical diagnosis of acute PID depends on the epidemiologic characteristics of the population, with higher PPVs among sexually active young women (particularly adolescents), women attending STD clinics, and those who live in communities with high rates of gonorrhea or chlamydia. Regardless of PPV, no single historical, physical, or laboratory finding is both sensitive and specific for the diagnosis of acute PID. Combinations of diagnostic findings that improve either sensitivity (i.e., detect more women who have PID) or specificity (i.e., exclude more women who do not have PID) do so only at the expense of the other. For example, requiring two or more findings excludes more women who do not have PID and reduces the number of women with PID who are identified.

Many episodes of PID go unrecognized. Although some cases are asymptomatic, others are not diagnosed because the patient or the health-care provider fails to recognize the implications of mild or nonspecific symptoms or signs (e.g., abnormal bleeding, dyspareunia, and vaginal discharge). Even women with mild or asymptomatic PID might be at risk for infertility (740). Because of the difficulty of diagnosis and the potential for damage to the reproductive health of women, health-care providers should maintain a low threshold for the diagnosis of PID (729). The following recommendations for diagnosing PID are intended to help health-care providers recognize when PID should be suspected and when additional information should be obtained to increase diagnostic certainty. Diagnosis and management of other common causes of lower abdominal pain (e.g., ectopic pregnancy, acute appendicitis, ovarian cyst, and functional pain) are unlikely to be impaired by initiating antimicrobial therapy for PID.

Presumptive treatment for PID should be initiated in sexually active young women and other women at risk for STDs if they are experiencing pelvic or lower abdominal pain, if no cause for the illness other than PID can be identified, and if one or more of the following minimum clinical criteria are present on pelvic examination:

  • cervical motion tenderness
    or
  • uterine tenderness
    or
  • adnexal tenderness.

The requirement that all three minimum criteria be present before the initiation of empiric treatment could result in insufficient sensitivity for the diagnosis of PID. After deciding whether to initiate empiric treatment, clinicians should also consider the risk profile for STDs.

More elaborate diagnostic evaluation frequently is needed because incorrect diagnosis and management of PID might cause unnecessary morbidity. For example, the presence of signs of lower-genital–tract inflammation (predominance of leukocytes in vaginal secretions, cervical exudates, or cervical friability), in addition to one of the three minimum criteria, increases the specificity of the diagnosis. One or more of the following additional criteria can be used to enhance the specificity of the minimum clinical criteria and support a diagnosis of PID:

  • oral temperature >101°F (>38.3°C);
  • abnormal cervical mucopurulent discharge or cervical friability;
  • presence of abundant numbers of WBC on saline microscopy of vaginal fluid;
  • elevated erythrocyte sedimentation rate;
  • elevated C-reactive protein; and
  • laboratory documentation of cervical infection with N. gonorrhoeae or C. trachomatis.

Most women with PID have either mucopurulent cervical discharge or evidence of WBCs on a microscopic evaluation of a saline preparation of vaginal fluid (i.e., wet prep). If the cervical discharge appears normal and no WBCs are observed on the wet prep of vaginal fluid, the diagnosis of PID is unlikely, and alternative causes of pain should be considered. A wet prep of vaginal fluid also can detect the presence of concomitant infections (e.g., BV and trichomoniasis).

The most specific criteria for diagnosing PID include:

  • endometrial biopsy with histopathologic evidence of endometritis;
  • transvaginal sonography or magnetic resonance imaging techniques showing thickened, fluid-filled tubes with or without free pelvic fluid or tubo-ovarian complex, or Doppler studies suggesting pelvic infection (e.g., tubal hyperemia); or
  • laparoscopic findings consistent with PID.

A diagnostic evaluation that includes some of these more extensive procedures might be warranted in some cases. Endometrial biopsy is warranted in women undergoing laparoscopy who do not have visual evidence of salpingitis, because endometritis is the only sign of PID for some women.

Treatment

PID treatment regimens must provide empiric, broad spectrum coverage of likely pathogens. Several parenteral and oral antimicrobial regimens have been effective in achieving clinical and microbiologic cure in randomized clinical trials with short-term follow-up (741,742). However, only a limited number of investigations have assessed and compared these regimens with regard to elimination of infection in the endometrium and fallopian tubes or determined the incidence of long-term complications (e.g., tubal infertility and ectopic pregnancy) after antimicrobial regimens (730,735,743). The optimal treatment regimen and long-term outcome of early treatment of women with subclinical PID are unknown. All regimens used to treat PID should also be effective against N. gonorrhoeae and C. trachomatis because negative endocervical screening for these organisms does not rule out upper-reproductive–tract infection. The need to eradicate anaerobes from women who have PID has not been determined definitively. Anaerobic bacteria have been isolated from the upper-reproductive tract of women who have PID, and data from in vitro studies have revealed that some anaerobes (e.g.,Bacteroides fragilis) can cause tubal and epithelial destruction. BV is present in many women who have PID (731,734). Until treatment regimens that do not cover anaerobic microbes have been demonstrated to prevent long-term sequelae (e.g., infertility and ectopic pregnancy) as successfully as the regimens that are effective against these microbes, the use of regimens with anaerobic activity should be considered. Treatment should be initiated as soon as the presumptive diagnosis has been made, because prevention of long-term sequelae is dependent on early administration of appropriate antibiotics. When selecting a treatment regimen, health-care providers should consider availability, cost, and patient acceptance (742). In women with PID of mild or moderate clinical severity, parenteral and oral regimens appear to have similar efficacy. The decision of whether hospitalization is necessary should be based on provider judgment and whether the woman meets any of the following suggested criteria:

  • surgical emergencies (e.g., appendicitis) cannot be excluded;
  • tubo-ovarian abscess;
  • pregnancy;
  • severe illness, nausea and vomiting, or high fever;
  • unable to follow or tolerate an outpatient oral regimen; or
  • no clinical response to oral antimicrobial therapy.

No evidence is available to suggest that adolescents have improved outcomes from hospitalization for treatment of PID, and the clinical response to outpatient treatment is similar among younger and older women. The decision to hospitalize adolescents with acute PID should be based on the same criteria used for older women.

Parenteral Treatment

Several randomized trials have demonstrated the efficacy of parenteral regimens (734,741,742). Clinical experience should guide decisions regarding transition to oral therapy, which usually can be initiated within 24–48 hours of clinical improvement. In women with tubo-ovarian abscesses, at least 24 hours of inpatient observation is recommended.

Recommended Parenteral Regimens
  • Cefotetan 2 g IV every 12 hours
    PLUS
  • Doxycycline 100 mg orally or IV every 12 hours
    OR
  • Cefoxitin 2 g IV every 6 hours
    PLUS
  • Doxycycline 100 mg orally or IV every 12 hours
    OR
  • Clindamycin 900 mg IV every 8 hours
    PLUS
  • Gentamicin loading dose IV or IM (2 mg/kg), followed by a maintenance dose (1.5 mg/kg) every 8 hours. Single daily dosing (3–5 mg/kg) can be substituted.

Because of the pain associated with intravenous infusion, doxycycline should be administered orally when possible. Oral and IV administration of doxycycline provide similar bioavailability. Although use of a single daily dose of gentamicin has not been evaluated for the treatment of PID, it is efficacious in analogous situations.

When using the parenteral cefotetan or cefoxitin regimens, oral therapy with doxycycline 100 mg twice daily can be used 24–48 hours after clinical improvement to complete the 14 days of therapy.  For the clindamycin/gentamicin regimen,  oral therapy with clindamycin (450 mg orally four times daily) or doxycycline (100 mg twice daily) can be used to complete the 14 days of therapy. However, when tubo-ovarian abscess is present, clindamycin (450 mg orally four times daily) or metronidazole (500 mg twice daily) should be used to complete at least 14 days of therapy with doxycycline to provide more effective anaerobic coverage than doxycycline alone.

Limited data are available to support use of other parenteral second- or third-generation cephalosporins (e.g., ceftizoxime, cefotaxime, and ceftriaxone). In addition, these cephalosporins are less active than cefotetan or cefoxitin against anaerobic bacteria.

Alternative Parenteral Regimens

Ampicillin/sulbactam plus doxycycline has been investigated in at least one clinical trial and has broad-spectrum coverage (744). Ampicillin/sulbactam plus doxycycline is effective against C. trachomatisN. gonorrhoeae, and anaerobes in women with tubo-ovarian abscess. Another trial demonstrated high short-term clinical cure rates with azithromycin, either as monotherapy for 1 week (500 mg IV daily for 1 or 2 doses followed by 250 mg orally for 5–6 days) or combined with a 12-day course of metronidazole (745). Limited data are available to support the use of other parenteral regimens.

Alternative Parenteral Regimen
  • Ampicillin/Sulbactam 3 g IV every 6 hours
    PLUS
  • Doxycycline 100 mg orally or IV every 12 hours

Intramuscular/Oral Treatment

Intramuscular/oral therapy can be considered for women with mild-to-moderately severe acute PID, because the clinical outcomes among women treated with these regimens are similar to those treated with intravenous therapy (729). Women who do not respond to IM/oral therapy within 72 hours should be reevaluated to confirm the diagnosis and should be administered intravenous therapy.

Recommended Intramuscular/Oral Regimens
  • Ceftriaxone 250 mg IM in a single dose
    PLUS
  • Doxycycline 100 mg orally twice a day for 14 days
    WITH* or WITHOUT
  • Metronidazole 500 mg orally twice a day for 14 days
    OR
  • Cefoxitin 2 g IM in a single dose and Probenecid, 1 g orally administered concurrently in a single dose
    PLUS
  • Doxycycline 100 mg orally twice a day for 14 days
    WITH or WITHOUT
  • Metronidazole 500 mg orally twice a day for 14 days
    OR
  • Other parenteral third-generation cephalosporin (e.g., ceftizoxime or cefotaxime)
    PLUS
  • Doxycycline 100 mg orally twice a day for 14 days
    WITH* or WITHOUT
  • Metronidazole 500 mg orally twice a day for 14 days

*The recommended third-generation cephalsporins are limited in the coverage of anaerobes. Therefore, until it is known that extended anaerobic coverage is not important for treatment of acute PID, the addition of metronidazole to treatment regimens with third-generation cephalosporins should be considered (Source: Walker CK, Wiesenfeld HC. Antibiotic therapy for acute pelvic inflammatory disease: the 2006 CDC Sexually Transmitted Diseases Treatment Guidelines. Clin Infect Dis 2007;28[Supp 1]:S29–36).

These regimens provide coverage against frequent etiologic agents of PID, but the optimal choice of a cephalosporin is unclear. Cefoxitin, a second-generation cephalosporin, has better anaerobic coverage than ceftriaxone, and in combination with probenecid and doxycycline has been effective in short-term clinical response in women with PID. Ceftriaxone has better coverage against N. gonorrhoeae. The addition of metronidazole will also effectively treat BV, which is frequently associated with PID.

Alternative IM/Oral Regimens

Although information regarding other IM and oral regimens is limited, a few have undergone at least one clinical trial and have demonstrated broad-spectrum coverage. Azithromycin has demonstrated short-term clinical effectiveness in one randomized trial when used as monotherapy (500 mg IV daily for 1–2 doses, followed by 250 mg orally daily for 12–14 days) or in combination with metronidazole (745), and in another study, it was effective when used 1 g orally once a week for 2 weeks in combination with ceftriaxone 250 mg IM single dose (746). When considering these alternative regimens, the addition of metronidazole should be considered to provide anaerobic coverage. No data have been published regarding the use of oral cephalosporins for the treatment of PID. As a result of the emergence of quinolone-resistant N. gonorrhoeae, regimens that include a quinolone agent are no longer routinely recommended for the treatment of PID. If allergy precludes the use of cephalosporin therapy, if the community prevalence and individual risk for gonorrhea are low, and if follow-up is likely, use of fluoroquinolones for 14 days (levofloxacin 500 mg orally once daily, ofloxacin 400 mg twice daily, or moxifloxacin 400 mg orally once daily) with metronidazole for 14 days (500 mg orally twice daily) can be considered (747–749). Diagnostic tests for gonorrhea must be obtained before instituting therapy, and persons should be managed as follows.

  • If the culture for gonorrhea is positive, treatment should be based on results of antimicrobial susceptibility testing.
  • If the isolate is determined to be quinolone-resistant N. gonorrhoeae (QRNG) or if antimicrobial susceptibility cannot be assessed (e.g., if only NAAT testing is available), consultation with an infectious-disease specialist is recommended.

Other Management Considerations

To minimize disease transmission, women should be instructed to abstain from sexual intercourse until therapy is completed, symptoms have resolved, and sex partners have been adequately treated (See chlamydia and gonorrheasections). All women who received a diagnosis of acute PID should be tested for HIV, as well as GC and chlamydia, using NAAT.

Follow-Up

Women should demonstrate clinical improvement (e.g., defervescence; reduction in direct or rebound abdominal tenderness; and reduction in uterine, adnexal, and cervical motion tenderness) within 3 days after initiation of therapy. If no clinical improvement has occurred within 72 hours after outpatient IM/oral therapy, hospitalization, assessment of the antimicrobial regimen, and additional diagnostics (including consideration of diagnostic laparoscopy for alternative diagnoses) are recommended. All women who have received a diagnosis of chlamydial or gonococcal PID should be retested 3 months after treatment, regardless of whether their sex partners were treated (480). If retesting at 3 months is not possible, these women should be retested whenever they next present for medical care in the 12 months following treatment.

Management of Sex Partners

Men who have had sexual contact with a woman with PID during the 60 days preceding her onset of symptoms should be evaluated, tested, and presumptively treated for chlamydia and gonorrhea, regardless of the etiology of PID or pathogens isolated from the woman. If a woman’s last sexual intercourse was >60 days before onset of symptoms or diagnosis, the most recent sex partner should be treated. Male partners of women who have PID caused by C. trachomatis and/or N. gonorrhoeae frequently are asymptomatic. Arrangements should be made to link male partners to care. If linkage is delayed or unlikely, EPT and enhanced referral are alternative approaches to treating male partners of women who have chlamydia or gonococcal infections (see Partner Services) (93,94). Partners should be instructed to abstain from sexual intercourse until they and their sex partners have been adequately treated (i.e., until therapy is completed and symptoms have resolved, if originally present).

Special Considerations

Allergy, Intolerance, and Adverse Reactions

The cross reactivity between penicillins and cephalosporins is <2.5% in persons with a history of penicillin allergy (428-431,464). The risk for penicillin cross-reactivity is highest with first-generation cephalosporins, but is negligible between most second-generation (cefoxitin) and all third-generation (ceftriaxone) cephalosporins (428-431) (see Management of Persons who Have a History of Penicillin Allergy).

Pregnancy

Pregnant women suspected to have PID are at high risk for maternal morbidity and preterm delivery. These women should be hospitalized and treated with intravenous antibiotics.

HIV Infection

Differences in the clinical manifestations of PID between women with HIV infection and women without HIV infection have not been well delineated. In early observational studies, women with HIV infection and PID were more likely to require surgical intervention. More comprehensive observational and controlled studies have demonstrated that women with HIV infection and PID have similar symptoms when compared with HIV-negative women with PID (266,750,751), except they are more likely to have a tubo-ovarian abscess; women with HIV infection responded equally well to recommended parenteral and IM/oral antibiotic regimens as women without HIV infection. The microbiologic findings for women with HIV infection and women without HIV infection were similar, except women with HIV infection had higher rates of concomitantM. hominis and streptococcal infections. These data are insufficient for determining whether women with HIV infection and PID require more aggressive management (e.g., hospitalization or intravenous antimicrobial regimens).

Intrauterine Contraceptive Devices

IUDs are one of the most effective contraceptive methods. Copper-containing and levonorgestrel-releasing IUDs are available in the United States. The risk for PID associated with IUD use is primarily confined to the first 3 weeks after insertion (752,753). If an IUD user receives a diagnosis of PID, the IUD does not need to be removed (63). However, the woman should receive treatment according to these recommendations and should have close clinical follow-up. If no clinical improvement occurs within 48–72 hours of initiating treatment, providers should consider removing the IUD. A systematic review of evidence found that treatment outcomes did not generally differ between women with PID who retained the IUD and those who had the IUD removed (754). These studies primarily included women using copper or other nonhormonal IUDs. No studies are available regarding treatment outcomes in women using levonorgestrel-releasing IUDs.


繼續閱讀
2016/03/24

少女频繁手淫可能引发严重后果

一提到手淫许多人就联想起这是男子的事,似乎与女性无关,其实女性也有手淫习惯。据相关的调查发现,女性手淫的最高值达到68%,其中54%在15~18岁左右开始的,另外14%是在20岁以后才开始的。性健康教育专家认为:虽然适度手淫有利健康,但在少女时期,应将更多的注意力集中到学习,千万不要长期的、频繁的、无节制的手淫,否则影响身体健康成长!

少女频繁手淫可能引发严重后果少女频繁手淫可能引发严重后果

  1、过度手淫引发神经衰弱。

  手淫本身不会引起神经衰弱,而是因为这些人对手淫抱有不正确的认识,认为手淫是一种不道德,见不得人的下流行动,所有的手淫是对身体都害,浮想联翩,背上沉重的包袱。长时间的精神压力,会使大脑皮层处于持续兴奋状态,易出现疲劳,表现为注意力不集中,思维迟缓,反应迟钝等现象,若不能及时得到调整,最终出现神经衰弱。

  2、过度手淫后引发白带异常。

  女子的白带是由阴道粘膜的渗出液和子宫颈管内膜的分泌物组成,少量来自子宫和输卵管的分泌物。手淫的确会增加白带的数量。其原因:一是手淫造成强烈的性刺激,会骤然提高上述种种液体的分泌;二是手淫刺激下,性器官和盆腔里血液循环顿时加速,供血量显著增多。在血液循环丰富的状况下,白带的产量也会上升。至于外阴部的湿漉现象,除了由于白带增多缘故,还由于手淫的刺激引起外阴部前庭大腺,使其分泌液体润滑外阴的结果。

过度手淫会引起月经不调过度手淫会引起月经不调

  3、过度手淫会引起月经不调。


  4、过度手淫引发月经期下腹疼痛  月经周期与手淫之间没有直接的联系。体内性激素代谢,有条不紊地操纵着卵巢的功能和子宫内膜的变化。这种规律不会随手淫本身的机械性刺激而有所改动,正如婚后的性生活不会直接干预月经周期规律一样的道理。少女时代出现月经不调,多半是由于性激素代谢还不十分成熟与完善,容易受到精神紧张、环境变化、气候改变以及营养不良等因素的干扰,妨碍卵巢功能,于是经血增多或经期延长。倘若少女精神与心理状态比较稳定,即使手淫也未引起过多的恐惧与紧张,就不会由此诱发月经不调;反之,少女既有手淫,又恐惧、自责、紧张、焦虑、害怕手淫的“心理作用”十分显著,干扰了大脑皮层“司令部”,有时难免也会诱发月经不调。

  少女月经来潮时发生腹痛,这种情况叫痛经。发现原因现在不太清楚。但与子宫过度倾屈、子宫颈口狭窄等造成经血不能畅流有关。大量资料表明,无论手淫与否,少女发生痛经司空见惯。因此不能认为手淫是诱发痛经的一个因素。不过值得注意的是,手淫一旦促发性兴奋及至性高潮时,也会造成子宫一定程度的收缩。所以在月经来潮时手淫,有加重痛经程度的可能。

  5、手淫后引发妇科炎症

  手淫机械性刺激磨擦外阴部的动作,不但会直接刺激尿道口部,造成尿道口充血与水肿,而且不洁手淫,很容易造成细菌等病原体侵入尿道内,引起发炎,应及时去医院治疗。

 

文章关键词: 手淫 少女 严重 后果 过度


繼續閱讀
2016/02/11

高檢師及高營養師整理網路文章,分享李醫師談IC 間質性膀胱炎

談間質性膀胱炎的飲食療法

問:李醫師您好,我今年三十五歲,因頻尿、下腹部痛、夜尿多次求診,被診斷 為間質性膀胱炎,現在以膀胱灌注藥物效果不錯,但如果吃東西不小心(如香焦、柑橘)就會產生症狀加劇的情形,請問,何種食物較適合我們?飲食對於間質性膀胱炎到底有何影響?能不能藉由食物療法來治療間質性膀胱炎?

答:許多間質性膀胱炎(簡稱IC)患者發現改變飲食,可幫助控制病情及避免病情 復發,醫師及間質性膀胱炎協會(ICA)所收集的資料卻顯示:何種食物會引發症狀加劇是個人體質差異所致。

雖然有明白的指引可為大多數IC患者所接受,但發覺那種特別食物會引起症狀變化卻需要耐心。很多IC患者報告「限制食物」是一種有效的治療方式,且相信耐心付出是值得的,最近對IC患者調查的顯示,有百分之五十的人報告酸性、酒精性、含碳酸性飲料及咖啡、茶會加重他們的疼痛。

假如您想探索飲食在您的症狀中扮演的角色,最好的方式是剛開始時,食用多數IC患者認為可以忍受的食物,然後再慢慢增加其他的食物,嘗試少量多餐而非暴飲暴食,同時記錄飲食日誌,記錄每樣您食用的食物,幾周之後,開始食用被禁止的食物,每次一種,若食用後,疾病沒有復發,則可以繼續食用,若出現症狀加劇,則從您的飲食單上去除此東西,完成飲食的篩選之後,您可發現自己可忍受的困擾,嘗試每隔一周,少量加入食物,若症狀不致於復發厲害,則可不必完全禁止此類食物。

找出何者為需要限制的食物,是一相當漫長的過程,而且需要規則地執行,有時需求助營養師過敏專家,以下是建議可用及該避免的食譜:

牛奶/酪乳產品:
《避免》陳年乳酪、酸奶油、酸奶酪(優格)、巧克力。

蔬菜類:
《避免》青豆、洋蔥、豆腐、蕃茄。
 
水果類:
《避免》蘋果、香蕉、鳳梨、柑橘類水果、葡萄、桃子、梅子、石榴、草莓、杏類、梨、油桃、大黃根及上述成的果汁。

澱粉類及穀類:
《避免》裸麥及酵母麵包。

肉類及魚類:
《避免》過期罐頭、醃、燻、烤的肉類及魚類,鯷魚類、魚子醬、雞肝、醃牛肉、含有硝酸鹽或亞硝酸的肉類。

堅果類:
《避免》大部份堅果。

飲料類:
《避免》含酒精飲料、啤酒、含碳酸飲料、咖啡、茶、葡萄酒、蔓越莓果汁。

調味料:
《避免》法式蛋黃醬(美爾乃滋)、味精、辛辣食物(尤其是廣東菜、印度菜、墨西哥菜、泰國菜)、醬油、沙拉調味汁、醋。

防腐劑及添加物:
《避免》酒精苯、檸檬酸、砂糖、單鈉麩酸胺、含人工色素之食物。

其他:
《避免》煙草、咖啡因、鹼肉食物、興奮劑、含有麻黃素或偽麻黃素的抗過敏及感冒藥含有添加物的維他命。

雖然上述的避免食物似乎會嚇著你,但請記住仍然有很多其他食物可享用,很多患者說米飯、馬鈴薯、通心粉、蔬菜、肉類、雞肉,最不會引起困擾,以此為基準,您可建立有營養又有口味的食譜,同時可添加纖維質到飲食中以增進腸子蠕動:


若食用不該吃的食物時該怎麼辦?
若發生吃了會引起反應的食物時,請食用一杯含一湯匙碳酸氫鈉的水,如此可以鹼化尿液,避免酸性物質到尿液中刺激膀胱,有些人採取此法作為預防性,但若有心臟或高血壓問題,應和醫師討論之,因為碳酸氫鈉含有高濃度的鈉鹽、鹽,引起水份滯留於體內。此外若症狀復發時,可飲用大量水以稀釋尿液。

改變飲食習慣來控制IC是一種挑戰,在經過一段時間的嘗試錯誤後,若仍然無法找到您的理想食譜,請勿氣餒,此過程需要時間及耐心,但最終結果是值得等待的,您將會有美好的症狀經解。
繼續閱讀
2016/01/20

泌尿道感染披衣菌檢測及藥物相關分享

泌尿道感染披衣菌檢測及藥物相關分享

披衣菌檢測分享!!

1.醫院診所常用尿液常規檢查來看白血球或紅血球或細菌來看有無發炎加上披衣菌DNA PCR檢測,如果有發炎加上DNA PCR檢測(+) 則給你藥物治療,若尿檢一切正常則會跟你說你很好沒事啊!!

2.此時病患就會納悶我就有怪怪的感覺怎會檢查沒事,因為披衣菌感染的部位可能在
a.眼睛 / 砂眼披衣菌
b.呼吸道/  肺炎披衣菌
c.泌尿生殖系統 . 
d.其他
如果只做一般泌尿系統可能披衣菌DNA為陰性,但實務上常有抗體呈陽性的狀況

3.將時間倒轉10年 20年 30年,醫生是如何診斷披衣菌/chlamydia/衣原體感染
是使用披衣菌PCR檢測嗎?

4. 從傳統的濃度稀釋倍數1:幾倍,到數值 到現今的DNA檢測,時常會有盲點,如
a.披衣菌指數正常,披衣菌DNA異常
b.披衣菌指數異常  , 披衣菌DNA正常

甚至有人認為披衣菌指數Anti chla-IgG IgA IgM高都是偽陽性,只相信Chla-DNA PCR 的結果,請問是PCR結果(+)才能診斷開藥還是要配合病人臨床症狀輔助檢查報告開藥呢?

5.這時關鍵點就出現了,醫生該怎麼給藥? 病人有無症狀,病患敘述的症狀是否醫生採信,主觀與客觀的要件都要綜合評估

6.常遇到的問題,吃完藥沒覆檢。因此菌容易覆發,無法清楚是藥物使得披衣菌完全消滅或是免疫系統使得細菌完全排出體外

7.可以檢測的時間是什麼時候?接觸7-14天內,如果被感染約1週後就會有尿道口刺激若有似無,隱隱約約怪怪的感覺! a little bit burn felling!!  

8.披衣菌傳染途徑
(1)可經由受污染的手指,毛巾、洗臉用具或患者之眼分泌物接觸而感染:症狀為
結膜發炎(眼睛紅紅的會癢 像是血輪眼或是庫拉皮卡火紅眼,很多人去看眼科被說是過敏不用治療我也替病人覺得無奈)、上眼瞼結膜增生性結節,另常伴隨續發性細菌感染,沒治療最嚴重可能會失明,

(2)經由性接觸傳染:男性的症狀為分泌物,尿道球腺液(有點透明黏絲浮在馬桶水面),尿道炎,前列腺炎(可能會早洩或是射精帶血或是性交疼痛),附睪丸炎,花柳性淋巴肉芽腫等;女性則為尿道炎、子宮頸炎、子宮內膜炎、輸卵管炎、卵巢炎、骨盆腔發炎等,是現今不孕的原因之一。

超過50%以上男性及80%以上女性感染的人沒症狀!!!
目前是全世界性傳染病最頻繁的感染源之一

(3)若懷孕婦女生殖道感染,則新生兒經由母體產道生出時亦有可能被傳染此菌。

9.治療1週-2週後就能完全殺死披衣菌嗎?
通常初次感染早期發現皆可以早期治療,重點是藥的劑量與服藥禁忌及其他注意事項
像1.tetracycline  四環素
   2.erythromycin, Clarithromycin 紅黴素類
   3. azithromycin 日舒 有醫院一次給4顆 1g 。 梅毒患者無針劑治療時給予2g
   4. doxycycline  
   5. minocycline
   6. ofloxacin ,ciprofloxacin
   7. clindamycin
   8. 其他藥物 美國有研究一顆藥解決(聽外國病人轉述的@@)
   9. 針劑
   10.尖端醫學/奈米治療  與披衣菌大小有關,需要比他分子更小的才能消滅
   
10.為什麼披衣菌一直治療不好?
a.如有合併感染其他細菌或病毒會延長治療時間,所以要檢查清楚是否有感染其他菌
b.沒有按時服藥,因披衣菌體積小易躲藏且複製速度非常快,能躲避及辨識藥物攻擊
與其醣蛋白受體接受器有關,其基體與包涵體雖會被巨噬細胞攻擊吃進去,但披衣菌很厲害它不怕,它還能在裡面繼續繁殖複製,等細胞養分用完之後破殼而出繼續攻擊複製,源源不絕
c.熬夜,免疫系統差
d.水喝太少,菌排不出,易造成逆行性感染
e.喜歡吃刺激的,太辣/太鹹/太甜/太酸/重口味
f.體重過重:藥物濃度不足,與藥物動力學有關,建議減重
g.披衣菌抗藥性!!!  
h.攝護腺肥大
i.乒乓球效應 ,治療好後又被另一半感染,造成反覆治療無效 ,滿常見的
j.變種披衣菌

11.目前追蹤最久的案例是多長:
超過1年以上,指數異常而DNA正常,臨床症狀未改善

12.披衣菌區分為常見三種, 了解即可
1.砂眼披衣菌(Chlamydia trachomatis)
2.鸚鵡披衣菌(Chlamydia psittaci) ˋ
3.肺炎披衣菌(Chlamydia pneumoniae),

13.披衣菌其外膜蛋白可分為 19 種型

 A、B、Ba 和 C 型與失明及慢性結膜炎有關。 D -K型與生殖泌尿道感染有關,例如尿道炎、副睪丸炎、子宮頸炎、輸卵管炎、 骨盆腔炎與子宮外孕等。 L1-L3 常與花柳性淋巴肉芽腫 (lymphogranuloma venereum, LGV) 的發生相關。 G、I 與 D 可能與子宮頸鱗狀上皮細胞癌的形成有關,K 型 的慢性感染已確認與不孕症有關

14.披衣菌有打針治療或疫苗嗎?
疫苗研究開發中!!   打針治療效果有限!!!

15.營養輔助有哪些?
1.鋅
2.維他命C
3.南瓜子
4.茄紅素
5.其他(花粉類/菊科類/中草藥)

16.建議檢測方式:

1.高檢師建議披衣菌DNA 及血清抗體IgG IgA IGM 同時檢測 !!!
2.其中包含 血液+尿液+細胞+特殊採樣  四種系統完整分析 

17.感染披衣菌造成不孕的可能原因:

1.降低男性精蟲活性 : 披衣菌會造成精蟲活性不足+游的慢根本無法與卵子結合
2.影響精蟲品質 : 披衣菌會黏於精子的頭上造成品質不良使其無法有效與卵子結合
3.精蟲數量不足 : 正常男性有億萬大軍,若<6000萬子弟兵,我想是很難攻下的
4.精液量 : 披衣菌會稀釋精液量,量不足加上精子營養來源不足。想當然爾 無法受孕
5.子宮頸;輸卵管發炎;輸卵管沾黏;輸卵管賭塞,卵子出不來,或是卵子品質不佳
6.子宮環境受影響、常造成子宮外孕
7.細菌使得荷爾蒙受影響



 與高檢師預約




 
繼續閱讀
2016/01/05

一、何謂尿道炎

參考資料 國家網路醫院 免費醫療諮詢
尿道炎的分類非常複雜,範圍很廣,大致上可分為:

1.非性行為所引起的尿道炎:如外傷精神刺激、全生性感染病發引起,代謝異常、過敏、長瘤等。
2.由性行為或類似性行為所引起的尿道炎:
‧淋菌性尿道炎是由感染淋病雙球病引起的尿道炎。
‧非淋性尿道炎,是由淋菌以外的微生物所引起的尿道炎,長見的有披衣菌,黴漿菌等,其症狀雖較淋病輕 微,但它造成的危害並不遜於淋病對健康所導致的不良影響。

二、致病原分類
1.細菌性:如披衣菌、葡萄球菌、徽漿菌、大腸菌、變形桿菌..等等。 
※披衣菌是介於細菌與病毒的微生物,它和病毒一樣寄居在人體細胞內生活,形成一件外衣,進入人 體後在細胞寄生,一有機會就脫去「外衣」開始肆虐,這也是臨床上病人發病的時候了,在非淋菌 性尿道炎的病原中有50%以上是由披衣菌引起的,淋菌性尿道炎有60%同時感染披衣菌,其潛伏期 約7-14天,甚至長達六星期。
2.病毒性:如生殖器單純庖疹病毒、巨細胞病毒等。 
3.原蟲性:如滴蟲、阿米巴蟲等。 
4.黴菌性:如白色念球菌。 

三、症狀及併發症
1.淋菌性尿道炎: 
‧男性:尿道流膿、灼熱、刺痛、排尿疼痛,可併發輸精管阻塞、不孕症,亦可侵犯眼睛、心臟、骨盆腔等引發嚴重之合併症。
‧女性:白帶增多,異色異味(80%自覺症狀不明顯),可併發輸卵管阻塞、骨盆腔炎、子宮外孕、不孕症。

2.非淋菌尿道炎: 
‧男性:症狀較淋病緩和,病人偶而在清晨發現尿道口有些黏液狀或透明分泌物,自覺排尿時搔癢感,灼熱感、微痛,併發攝護腺炎,副睪丸炎、尿道狹窄等。
‧女性:陰道分泌物多、呈黃色、子宮頸炎、小便灼熱感、頻尿、陰部悶痛、小腹發脹、自覺症狀較少,約80%無症狀,可併發骨盆腔炎、不孕症,如懷孕期間感染,引起流產、早產、死胎的機會很高。

四、預防方法
1.安全可靠的性伴侶。 
2.避免無保護的性行為。
3.避免黏膜及插入性的接觸。 
4.全程、正確使用保險套。 
5.事後用溫水漱口及沖洗(小腹以下)。 
6.注重個人衛生習慣。 

五、患者注意事項
1.如果懷疑自己已受感染應速就醫,並遵照醫囑檢查治療。 
2.切勿自行亂服成藥物,以免延誤病情。 
3.內褲與家人衣物分開洗滌。 
4.多飲水。 
5.配偶或接觸者一同接受檢查、治療。 
6.病癒後應依醫師指示陸續接受定期檢查。 
7.必須做梅毒和愛滋病抗體的篩檢。
繼續閱讀
2015/04/26

泌尿道感染久治不癒原因。厭氧菌。

針對男性泌尿道感染久治不癒目前有三種厭氧菌是高檢師比較常驗到的跟大家分享

1.Propionibacterium acnes 痤瘡丙酸桿菌
2.Dermabacter hominis
3.Corynebacterium glucuronolyticum
補充:如果有細菌性攝護腺炎的朋友們可以於泌尿科看診時主動告知醫師請幫忙作攝護腺按摩將前列腺液排出,當然配合正確抗生素治療及正確生活習慣及營養補充我想是對於症狀改善有正向的幫助

針對男生跟女生常驗出的細菌跟大家分享

1.Enterococcus faecalis  糞腸球菌
2.G(+)Bacilli 革蘭氏陽性桿菌
3.E-coli 大腸桿菌
4.Yeast  酵母菌
5.GBS  B型鏈球菌

藥物敏感性試驗常出現之抗藥性藥物
1.Ampicillin
2.ciprofloxacin
3.Gentamicin 
4.Clindamycin
5.Erythromycin
6.penicillin
7.tetracycline
8.SXT
9.SYN
10.MEM
繼續閱讀
2015/03/12

泌尿道感染。黴漿菌、尿漿菌、生殖道人型黴漿菌 Ureaplasma urealyticeem

黴漿菌是一類引致疾病的微生物.透過性接觸而感染的黴漿菌包括:尿漿菌(Ureaplasma urealyticeem) ,人型黴漿菌(Mycoplsma homonis)及生殖黴漿菌(Mycoplasma genitalium).黴漿菌所引致的生殖泌尿系統疾病與合併症與披衣菌引致的疾病相似.黴漿菌感染所引致的疾病可治癒。
非淋菌性尿道炎(NGU)的病原體包括披衣菌和黴漿菌,據報導,由黴漿菌感染引起的約占20 %~30 %.泌尿道黴漿菌包括人黴漿菌(Mycoplasm a hominis,Mh),尿漿菌(Ureaplasma urealyticum,Uu)和生殖道黴漿菌(Mycoplasmagenitalium,Mg);可引起尿道炎、子宮頸炎、子宮內膜炎、輸卵管炎、前列腺炎、附睾炎等,近幾年來其發病率逐年提高。
據美國CDC 報導 NGU 患者中 25%~55%的病例由沙眼披衣菌(Chlamydiatrochomatis Ct)引起;20%~40%的病例由尿素黴漿菌(Ureaplasma urealyticum Uu)引起;2%~5%的病例由陰道毛滴蟲引起;單純皰疹病毒偶跠是NGU 的病因 尚有少數病例病因目前尚不明了。黴漿菌(Mycoplasma)廣泛分佈於自然界 有80 餘種 與人類有關的黴漿菌有肺炎黴漿菌(M.pneumonie Mp)、人型黴漿
菌 (M.hominis Mh)、尿素黴漿菌(Ureaplasma urealyticum Uu)和生殖黴漿菌(M.genitalium Mg),前者引起肺炎,後者引起泌尿生殖系統感染。
黴漿菌是一類能通過細菌濾器沒有細胞壁及前體形態呈多形性屬於軟皮體綱的一種原核微生物是目前所知能在無生命培養基中生長繁殖的最小微生物。黴漿菌由二分裂繁殖,形態多樣,基本呈球形和絲形,黴漿菌可在雞胚絨毛尿囊膜上或細胞培養中生長,在一般培養基上無法生長。
生殖黴漿菌是新近被發現的黴漿菌 它是由Tully 等於1981 年首先從兩例非淋菌性尿道炎患者尿道標本分離出來的;有資料表明,生殖黴漿菌是泌尿道和生殖道感染的病原體之一,具有性傳播性,而且泌尿道和生殖道可能是生殖黴漿菌寄居或感染的原發部位。由於生殖黴漿菌體外分離培養顯示其生長緩慢,需要的營養成分複雜,所以從臨床標本中分離生殖黴漿菌非常困難。目前,生殖黴漿菌的檢測主要通過PCR 方法。
已有某些證據表明,人型黴漿菌可能是女性盆腔炎性疾病的病因,但沒有證據顯示尿素黴漿菌具有類似的作用。
據報導原體可減低精子的運動力和減少精子的數量,並和精子的異常外觀有關清除尿素黴漿菌可以改善精子的運動力、數量和外觀;雖然尿素黴漿菌可能和精子運動力的改變有關,但是沒有具體的證據表明尿素黴漿菌是不孕症的重要原因。
繼續閱讀
2015/01/03

[醫療] 半年的膀胱陰道炎全好啦^^

某天有位病人來檢查,他說是有人推薦我來找你做檢查,還轉貼相關相關資訊給我看,想說來看看內容,詳細看完之後,恩!沒錯。有幫他們做過檢查,也很開心他們在檢查後經過治療已經痊癒了。裡面也提到一些重點,希望各位網友可以參考

1.治療前可以先做檢查,了解是否有藥物抗藥性,要不然你怎嚜治療永遠都無效!
2.最好連另一半也做檢查,要不然治療好了之後又交互傳染,那以前治療的都白費呢!
3.健保治療雖然便宜,但是反覆治療無效後應該考慮換一間,這種感染的問題經驗很重要,其實整個醫療體系中,檢查的費用是最高的,其他都很便宜,你只要知道你被什麼感染,用對的藥治療就一切OK了!!想想你在醫院不會沒做檢查就說你有癌症就開始化療等治療程序吧,一定會經過種種檢測,包括高階影像醫學等等綜合各種數據才下診斷,當各位聽到什麼泌尿道感染 感冒 這種簡單的名詞的時候一定要提出問題,這些都是症狀,重要是你要了解是什麼原因導致你感染!!!!是什麼細菌或是什麼病毒!

4.女生婦科重點檢測項目一.小便檢查 二.陰道分泌物培養 三.菜花檢測
5.男生重點檢測項目,若是年紀輕輕有頻尿的問題就該注意 一.小便檢查(最好可以分前段尿與中段尿做檢測,常在醫院或是診所留中段尿檢查總是正常的要注意)二.攝護腺炎檢測,若是感染到比較深層的位置我們必須透過特殊採樣才能判斷,當然泌尿科醫師的攝護腺按摩排毒排細菌也是不可少的!三.其他尿液細菌及症狀檢測

男生/女生治療中保養良方
1.除了藥物治療外其實最好的方式就是多喝水 多排尿 不要憋尿 
2.開始做有氧運動,如慢跑或是游泳
3.益生菌,甘露醣,蔓越莓錠,無糖蔓越莓汁,維他命C,梅子,男女都可以吃
4.治療中避免吃刺激性飲食,如太辣,太鹹等重口味
5.避免治療中喝過多的茶及含咖啡因飲品
6.性行為喝開水,並排空尿液
7.大便後由前往後擦拭,避免大腸桿菌.造成尿道感染
8.避免久坐,太緊的內衣褲,牛仔褲
9.注意公共衛生,避免直接接觸公共廁所馬桶
10.改棉質的內衣褲
11.藥物治療到一個階段勿覺得症狀緩解就自行停藥,細菌有可能會產生抗藥性
12.藥物治療完之後隔一週,此時體內藥物代謝完之後要看體內還有沒有細菌,追蹤複檢一次了解治療成效
繼續閱讀
2014/12/15

天冷泡湯注意事項

天冷泡湯注意事項
1.避免在很累的時候去泡湯,很累的時候就代表身體免疫力可能會處於低下,當免疫力低下時去泡湯就很容易出現泌尿道感染,此時應在家好好休息。
2.無論是熱湯或冷湯,裡面的溫度都很適合各種細菌生長,若是有泡湯後出現發燒 頭暈 想吐 請盡速檢查就醫
3.避免一次泡湯泡太久,應以15-30分鍾為限
4.避免一個人泡湯
5.有心血管疾病或是正在服用特殊藥物患者應避免泡湯
6.泡湯後溫差過大,需注意保暖
7.避免飽餐後泡湯
8.避免泡湯中或是泡湯後進行危險激烈活動
9.泡湯前與後應適量補充水分
10.注意地面濕滑及安全呼叫方式及手機緊急聯絡


繼續閱讀
2014/12/01

D-甘露糖D-Mannose與泌尿道感染

甘露糖D-mannose奈米膏狀維他命C 代訂購請洽高營養師/高檢師
LINE ID  kenkenupup 
手機 0977225181
感謝多位朋友們採用D-mannose產品,建議若無IC(間質性膀胱炎)可搭配使用奈米膏狀維他命C蔓越莓

當然最重要的是服用期間要避免熬夜,避免酒精、避免性行為避免手淫、每日喝水量應達自己的體重x35才足夠幫助細菌排出。

D-甘露糖是一種簡單的糖,天然存在於多種植物中,包括蔓越莓,藍莓,桃子,橙子,和蘋果。超市的蔓越莓汁往往含有太多果糖,這將使治療尿路感染變得沒有效。
 在治療尿路感染,證明和抗生素同樣有效,但沒有抗生素的副作用。
它對糖尿病患者是安全的,因為它不干擾血糖調節。
 它在尿路像一種磁鐵,吸引任何大腸桿菌,並防止其附著於膀胱內層。
細菌附著在D-甘露糖分子,並與正常尿流清除至體外。
 對於持續感染,D-甘露糖劑量是每隔幾小時溶解1茶匙在液體,持續三天。D-甘露糖的療效,通常在24小時內有效。如果72小時內發現沒有變化,它可能不是大腸桿菌引起的。
 D-甘露糖粉末也可以用來作為一種復發性感染預防性措施。
在傳統的醫學界還是比較陌生,已經有許多研究報告證明D-甘露糖的安全性,以及其對細菌大腸桿菌的效果。

繼續閱讀
2014/11/25

泌尿道感染久治不癒的原因

泌尿道感染久治不癒的原因。
1.口服抗生素產生抗藥性 
2.塞劑濫用生抗藥性,或是自己覺得好像好一點的時候就停藥,治療不完全,治療完後隔一週要進行覆檢以了解治療成效
3.沒有做檢查而盲目的在治療,重點是水水們要了解自己被什麼感染
4.婦科清潔
5.肉吃太多>>動物性荷爾蒙導致女生婦科pH值改變>>增加細菌繁殖
6.重口味/太辣/太鹹/太酸>>體質酸鹼度改變
7.熬夜>>造成免疫功能下降>>伺機性感染
8.喜歡穿比較緊的貼身衣物>>女生如小丁/緊身褲,男生如子彈內褲/很貼的牛仔褲
9.喜歡憋尿>>生理結構問題,細菌易孳生
10.水喝不夠>>細菌無法排出
11.緊張/壓力/神經型
12.經期前後以外的時間點分泌物是否過多
繼續閱讀
1